773874-06-9

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2,3-difluoro-4-Methylbenzoate is used as an intermediate in the synthesis of various pharmaceutical compounds, contributing to the development of new drugs and medications.
Used in Agrochemical Industry:
Methyl 2,3-difluoro-4-Methylbenzoate is also utilized in the production of agrochemicals, playing a role in the development of pesticides and other agricultural products to enhance crop protection and yield.
Used in Flavoring Agent:
Methyl 2,3-difluoro-4-Methylbenzoate is used as a flavoring agent in the food industry, adding unique taste profiles to various food products due to its strong aromatic properties.
Used in Synthesis of Organic Compounds:
As an intermediate, Methyl 2,3-difluoro-4-Methylbenzoate is essential in the synthesis of a range of organic compounds, expanding its applications across different chemical industries.
It is important to handle Methyl 2,3-difluoro-4-Methylbenzoate with care due to its potential for causing irritation to the skin, eyes, and respiratory system.

Upstream product

• 67-56-1 methanol 
• 261763-37-5 2,3-difluoro-4-methylbenzoic acid 

Downstream Products

• 863248-27-5 methyl 4-(bromomethyl)-2,3-difluorobenzoate 

Relevant academic research and scientific papers

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase

Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently marketed covalent BTK inhibitors is limited to oncology indications based on their suboptimal kinase selectivity. We describe the discovery and preclinical profile of LOU064 (remibrutinib, 25), a potent, highly selective covalent BTK inhibitor. LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases. It demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis. LOU064 is currently being tested in phase 2 clinical studies for chronic spontaneous urticaria and Sjoegren's syndrome.

Dual-acting antihypertensive agents

The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.